ISCB 2021: 42ND ANNUAL CONFERENCE OF THE INTERNATIONAL SOCIETY FOR CLINICAL BIOSTATISTICS
PROGRAM

Days: Monday, July 19th Tuesday, July 20th Wednesday, July 21st

Monday, July 19th

View this program: with abstractssession overviewtalk overview

14:00-14:30 Session P1: VIRTUAL POSTER ROOM : CLINICAL TRIAL DESIGN
14:00
An early-phase clinical trial design in oncology with generalization ability (abstract)
14:00
A flipped classroom approach for teaching medical statistics and statistical software training (abstract)
14:00
A comparison of dual biomarker threshold identification procedures within a confirmatory clinical trial (abstract)
14:00
Multifactor intervention efficacy on MACE and mortality in diabetic kidney disease: a cluster-randomized controlled trial (abstract)
14:00
Challenges in Factorial Design Randomized Control Trials (abstract)
14:00
Non-inferiority trials with indirect evidence of assay sensitivity using network meta-analysis (abstract)
14:00
Biomarker-based Bayesian randomized clinical trial for population finding with efficient reduction of sample size (abstract)
14:00
A methodological review of phase I designs with late-onset toxicities and incomplete follow-up (abstract)
14:00
Patient-specific dose finding in seamless phase I/II clinical trials (abstract)
14:00
The true power of clinical trials in pediatric cancers and other rare diseases (abstract)
14:00
Outcomes reported in randomized clinical trials of depression in geriatric patients: a methodological review (abstract)
14:00
One small clinical trial design to provide additional evidence of treatment effects than single-arm trials. (abstract)
14:00
SteppedPower - an R Package for Power Calculation in Stepped Wedge Cluster Randomised Designs (abstract)
14:00
Investigating the operating characteristics of clinical trials with borrowing from external data (abstract)
14:00
The influence of allocation bias in randomized clinical trials with binary response (abstract)
14:00
Introducing GINGER - a General simulation-INterpolation tool for designing multiGroup ExpeRiments (abstract)
14:00
Substitution of study control group by historic controls: Effect on study results using the example pain therapy for endometriosis (abstract)
14:00
Design optimization and intermediate safety reporting for a randomized controlled biomarker trial (abstract)
14:00
Using routinely collected data to conduct a pragmatic randomized controlled trial: an example addressing antibiotic prescription and resistance monitoring in Swiss primary care (abstract)
14:00
Statistical considerations in using a novel consensus building technique to estimate action thresholds in clinical decision making (abstract)
14:00
Flexible software framework to compare Bayesian hierarchical models across basket trial designs (abstract)
14:00
Assessment of Clinical Trial Missing Data During a Pandemic: A Tipping Point Analysis Case Study (abstract)
14:00-14:30 Session P2: VIRTUAL POSTER ROOM : LONGITUDINAL DATA ANALYSIS
14:00
A comparison of multiple imputation strategies for handling missing data in repeatedly measured multi-item scales (abstract)
14:00
A Hidden Markov model segmentation to identify trajectories in sleep apnoea patients (abstract)
14:00
A comparison of statistical methods to compensate for missing data in longitudinal cluster-randomised trials (abstract)
14:00
Effect of impaired vision on physical activity from childhood to adolescence (abstract)
14:00
Predictors of Multidrug Resistance in Nosocomial Pneumonia among Intensive Care Units’ Patients of a Tertiary Hospital, Egypt (abstract)
14:00
Modelling of longitudinal data to predict cardiovascular disease risk: a methodological review (abstract)
14:00
Impact of model misspecification on model-based bioequivalence (abstract)
14:00
Cluster randomised controlled trial of lifestyle intervention for adolescents’ health using ‘SPRAT’ programme (abstract)
14:00
Assessing the role of hyperventilation in patients with traumatic brain injury: longitudinal data analysis from the CENTER-TBI (abstract)
14:00
A new approach to measure frailty in the context of COVID-19 population (abstract)
14:00
Pain Management in Immediate Life Support Ambulances (abstract)
14:00
Statistical methods for estimating sources of variability in count-based biomarkers (abstract)
14:00
Longitudinal progression of frailty in older population and risk of adverse events: An application of joint models (abstract)
14:00
Semi-variogram approach to estimate within-subject variability in repeated measurements (abstract)
14:00
Non-linear dynamic indices summarize densely sampled longitudinal data (abstract)
14:00
Kernel density estimation for circular data about COVID-19 in the Czech Republic (abstract)
14:00
Functional analysis of temporal data about patient’s health condition after total knee replacement (abstract)
14:00
Multivariate Analysis of Blood Biomarkers in Amyotrophic Lateral Sclerosis (abstract)
14:00
Possibilities and challenges when analysing large longitudinal data from a population based Norwegian registry (MoBa study). (abstract)
14:00
Estimating time to confirmed disease progression in observational data sources with irregular visit schedules (abstract)
14:45-16:15 Session IS1: INVITED : Modelling the global spread of Covid19 and impact of interventions
14:45
Nowcasting the spread of COVID-19 to inform control policies in Hong Kong (abstract)
15:15
Statistical challenges in the monitoring of the SARS-CoV-2 pandemic (abstract)
15:45
Modelling the COVID-19 pandemic: initial introduction, lockdown assessment, phasing out (abstract)
14:45-16:15 Session OC1A: Mendelian randomisation & causal inference
14:45
How to deal with collider bias in Mendelian randomization analysis? (abstract)
15:03
The impact of instruments’ selection on Mendelian randomization results: a case study (abstract)
15:21
Caution When Inferring the Effect Direction in Mendelian Randomization (abstract)
15:39
Tying research question and analytical strategy when variables are affected by medication use (abstract)
15:57
Identification of causal effects in case-control studies (abstract)
14:45-16:15 Session OC1B: Bayesian clinical trial design (1)
14:45
Modular components in basket trials and connections among the applied tools (abstract)
15:03
Seamless Master Protocol with account for correlations within subgroups (abstract)
15:21
Monotonicity Rules for Inference in Basket Trials (abstract)
15:39
Response-adaptive randomization in clinical trials: from myths to practical considerations (abstract)
15:57
Treatment allocation strategies for umbrella trials in the presence of multiple biomarkers: A comparison of methods (abstract)
14:45-16:15 Session OC1C: Network meta analysis
14:45
Loop-splitting in network meta-analysis: a new approach to evaluating loop inconsistency (abstract)
15:03
Decision curve analysis for treatment benefit in a network meta-analysis framework (abstract)
15:21
The Risk Of Bias due to Missing Evidence in Network meta-analysis (ROB-MEN) tool: web application and implementation in a network of antidepressant drugs (abstract)
15:39
Network meta-analysis and random walks (abstract)
15:57
Bayesian network meta-analysis methods for combining IPD and aggregate data from single-arm studies and RCTs (abstract)
14:45-16:15 Session OC1D: Omics and genetic studies
14:45
ATLASQTL and EPISPOT: two joint hierarchical approaches for detecting and interpreting hotspots in molecular QTL studies (abstract)
15:03
Explained Variation in the Linear Mixed Model (abstract)
15:21
Reconstructing KIR haplotypes taking ambiguous and missing data into account (abstract)
15:39
COMET: an R package to identify sample cross-contamination in whole genome sequencing studies (abstract)
15:57
Evaluating DNA sequencing performance: concordance-discordance model and latent class model (abstract)
14:45-16:15 Session OC1E: multiple testing and randomization tests
14:45
Confidence intervals for the treatment effect in the Magnusson-Turnbull adaptive enrichment design (abstract)
15:03
Graphical approaches for the control of generalized error rates (abstract)
15:21
Evaluation of the Fill-it-up design to combine data from observational trials and RCTs (abstract)
15:39
Improved group sequential Holm procedures for testing multiple correlated hypotheses over time (abstract)
15:57
Randomization tests to address disruptions in clinical trials (abstract)
14:45-16:15 Session OC1F: Methods for survival analysis
14:45
Testing for ignorable sampling bias under random double truncation (abstract)
15:03
A martingale based approach for modelling the alternating recurrences in Cystic Fibrosis patients (abstract)
15:21
Impact of measurement error in time-varying prescription-based drug exposures in time-to-event analysis (abstract)
15:39
Developing a Goodness of fit test for a joint model: The case of clustered survival and count data (abstract)
15:57
Confidence bands of the MRL function in some right censored prevalent cohort studies via the empirical likelihood (abstract)
14:45-16:15 Session OC1G: mixed effects model
14:45
Bayesian multi-response nonlinear mixed-effect model: application of two recent HIV infection biomarkers (abstract)
15:03
Confidence, Prediction, Tolerance Intervals in Linear Mixed Models: Applications in (Non)-Clinical Trials (abstract)
15:21
Bayesian multivariate longitudinal data analysis assuming different association structures (abstract)
15:39
The use of mixed logistic modelling in the analysis of HIV latency study data in the context of low sample size and low outcome rates (abstract)
15:57
Mixed Modeling of Regional Infant Mortality Data over Twenty Years in North Rhine-Westphalia. (abstract)
16:15-16:45 Session P3: VIRTUAL POSTER ROOM : CAUSAL INFERENCE
16:15
STATISTICAL METHODS TO ANALYSE ORDINAL CATEGORICAL DATA ARISING FROM THE CLINICAL TRIAL OF DRUGS FROM THE PHARMACEUTICAL INDUSTRY (abstract)
16:15
Causal inference with skewed outcome data: Moving beyond the “ignore or transform” approach (abstract)
16:15
Marginal Structural Models with Latent Class Growth Modeling of Time-varying Treatment. (abstract)
16:15
Multidimensional mediators: Comparison between statistical methods using Data simulation (abstract)
16:15
The role of the matching algorithm in an analysis of the effect of hemoadsorption in patients with sepsis (abstract)
16:15
Estimating the causal effect of direct-acting antiviral agents on kidney function in a clinical cohort of chronic Hepatitis C patients (abstract)
16:15
Should multiple imputation be stratified by exposure when estimating causal effects via outcome regression? (abstract)
16:15
Pathways to inequalities in child mortality: a population level study in Wales (abstract)
16:15
Target Trial Emulation and Missing Eligibility Data: A study of Palivizumab for child respiratory illness (abstract)
16:15
Targeted causal quantile estimation for measurement of postdischarge opioid use in a text-to-web survey (abstract)
16:15
Does early weight gain mediate the causal effects of severity and duration of depression on the onset of metabolic syndrome? (abstract)
16:15
Pathway specific population attributable fractions. (abstract)
17:00-18:30 Session IS2: INVITED : Personalized Medicine with Dynamic Predictions
17:00
Personalized Schedules for Invasive Diagnostic Tests: With Applications in Surveillance of Chronic Diseases (abstract)
17:30
Comparing risk prediction models in longitudinal context (abstract)
18:00
Testing for Heterogeneity in the Utility of a Surrogate Marker (abstract)
17:00-18:30 Session OC2A: Mediation analysis
17:00
Nonlinear mediation analysis with high‐dimensional mediators whose causal structure is unknown (abstract)
17:18
Separable Causal Effects as alternative Estimands in Epidemiology and Biostatistics (abstract)
17:36
Simulating hypothetical interventions on multiple mediators: Extending methods and practical guidance (abstract)
17:54
Mediation with a survival outcome and time-varying mediator: empirical comparison and use in observational data (abstract)
18:12
Mediation with Irregular Longitudinal Biomarkers: An Application to Examining Obesity and Severe Disease in COVID-19 Patients (abstract)
17:00-18:30 Session OC2B: Bayesian clinical trial design (2)
17:00
Early completion of phase I cancer clinical trials with Bayesian optimal interval design (abstract)
17:18
Decision rules for identifying combination therapies in open-entry, randomized controlled platform trials (abstract)
17:36
A Bayesian decision-theoretic approach to outcome-adaptive sequential multiple assignment randomised trials (SMARTs) with distinct intermediate binary endpoints (abstract)
17:54
Modelling time varying recruitment rates and site activation prediction in multicentre clinical trials: A comparison study. (abstract)
18:12
Compromise Bayesian test decisions under type I error rate constraint (abstract)
17:00-18:30 Session OC2C: Epidemic modelling of COVID19
17:00
Dynamic predictive modelling of the first wave of the COVID-19 pandemic in Canada using a deterministic density-dependent susceptible-exposed-infected-recovered (SEIR) model that accounts for age-stratified ageing, reporting delays and mortality risks. (abstract)
17:18
Nowcasting CoVID-19 Deaths in England by Age and Region (abstract)
17:36
An evaluation of the stability, precision and performance of phenomenological models applied to COVID-19 cases and deaths in South Africa (abstract)
17:54
Estimation of incubation time and latency time distribution of SARS-CoV-2: the impact of distributional assumptions (abstract)
18:12
Regional estimates of reproduction numbers with application to COVID-19 (abstract)
17:00-18:30 Session OC2D: Meta-analysis : network and other
17:00
Quantifying the robustness of primary analysis results: a case study on missing outcome data in pairwise and network meta-analysis (abstract)
17:18
Meta-analysis of randomised trials with continuous outcomes: methods that adjust for baseline should be used (abstract)
17:36
Flexible generic framework for evidence synthesis in health technology assessment (abstract)
17:54
Component Network Meta-Analysis Including Individual Participant Data and Summary Aggregate Data (abstract)
18:12
Bayesian multivariate network meta-analysis model for the difference in restricted mean survival times (abstract)
17:00-18:30 Session OC2E: Some thought on research in biostatistics
17:00
Phases of methodological research in biostatistics – a proposal to increase transparency and reproducibility (abstract)
17:18
The p-value conundrum: how can a Bayesian analysis help? A case study in reproductive and maternal-fetal medicine (abstract)
17:36
On the marginality principle, with a focus on ratios and interactions (abstract)
17:54
An extension to reporting guidelines for systematic reviews of prediction model studies (TRIPOD-SRMA) (abstract)
18:12
Reference based multiple imputation for trials – what’s the right variance and how to estimate it? (abstract)
17:00-18:30 Session OC2F: methods for analysis of electronic health records
17:00
Immortal time bias for life-long conditions in retrospective observational studies using electronic heath records (abstract)
17:18
Identifying high-risk groups for BMI change using electronic health records from 2.3 million adults (abstract)
17:36
Multiple imputation of sporadically-missing continuous time data by Brownian bridge stochastic interpolation (abstract)
17:54
Handling missing data from wearable devices in clinical trials (abstract)
18:12
Using wristwear device to assess impact of COVID19 lockdown on physical activity (abstract)
17:00-18:30 Session OC2G: Analysis of gene expression and omics data
17:00
Prostate cancer intratumor heterogeneity assessment by depth measures analysis on imaging texture features (abstract)
17:18
Investigating Down syndrome by integrating methylation and glycomics using supervised PO2PLS (abstract)
17:36
Model selection characteristics when using MCP-Mod for dose-response gene expression data (abstract)
17:54
Information sharing across genes for improved parameter estimation in dose-response curves (abstract)
18:12
A Bayesian approach to estimating dynamic models of co-regulated gene expression (abstract)
18:30-19:00 Session P4: VIRTUAL POSTER ROOM : HIGH DIMENSIONAL DATA
18:30
A methodological approach to assess data quality from the Clinical Practice Research Datalink (abstract)
18:30
Modeling Child Mortality in the presence of Clustering (abstract)
18:30
Nguyen’s Information Criteria (NIC) (abstract)
18:30
Long-term oral prednisolone exposure for bullous pemphigoid: a population-based study using ‘big data’ and missing data algorithms (abstract)
18:30
Exploring risk stratification in cardiomyopathies using a deep learning approach for survival prediction (abstract)
18:30
Can animal studies on rodents help better understand Alzheimer’s disease in humans? (abstract)
18:30
Non-linear and non-additive associations between the pregnancy exposome and birthweight (abstract)
18:30-19:00 Session P5: VIRTUAL POSTER ROOM : MACHINE LEARNING
18:30
Machine learning to support Reinke’s edema diagnosis from voice recordings (abstract)
18:30
The Need for Expanded Standardized Reporting for Machine Learning Methods in Clinical Prediction (abstract)
18:30
Virtual biopsy in action: a radiomic-based model for CALI prediction (abstract)
18:30
Creation of adverse drug reactions assessment tool (abstract)
18:30
Use of machine learning models combined with innovative interpretation methods to identify prognostic factors (abstract)
Tuesday, July 20th

View this program: with abstractssession overviewtalk overview

13:00-14:30 Session IS3: INVITED : Optimal design of longitudinal cluster randomised trials
Discussant:
13:00
Faster and more agile designs: speeding up the stepped wedge with batched designs (abstract)
13:23
Longitudinal cluster randomised trials with continuous recruitment (abstract)
13:46
Optimal design of cluster randomized trials with baseline data comparing routine care to a new intervention (abstract)
13:00-14:30 Session OC3A: Propensity score in causal studies
13:00
Multiple imputation in propensity score matching: obtaining correct confidence intervals (abstract)
13:18
Effectiveness of screening colonoscopy in reducing colorectal cancer incidence: emulated target trials from German claims data (abstract)
13:36
Variance estimators for weighted and stratified linear dose-response function estimators using generalized propensity score (abstract)
13:54
Confounder selection strategies targeting stable treatment effect estimators (abstract)
14:12
Causal inference for combining RCTs and observational studies: methods comparison and medical application (abstract)
13:00-14:30 Session OC3B: COVID19 modelling
13:00
Factors involved in COVID-19 prognosis of patients hospitalized in Campania Region. Findings from COVOCA Study (abstract)
13:18
Laplace approximations for fast Bayesian inference of the time-varying reproduction number under misreported epidemic data (abstract)
13:36
Evaluating the effectiveness of local tracing partnerships on NHS test and trace for Covid19 (abstract)
13:54
Accounting for time-dependant confounding variables in mechanistic ODE model: simulations and application to a vaccine trial (abstract)
PRESENTER: Melanie Prague
14:12
Interventions to control nosocomial transmission of SARS-CoV-2: a modelling study (abstract)
13:00-14:30 Session OC3C: Dynamic prediction
13:00
Individual dynamic prediction of clinical endpoint from large dimensional longitudinal biomarker history: a landmark approach (abstract)
13:18
Comparison of multiple dynamic predictive accuracies (abstract)
13:36
Spatio-temporal score driven modeling of resting state fMRI data (abstract)
13:54
Breast cancer risk prediction in mammography screening cohorts: an approach based on modeling tumor onset and growth (abstract)
14:12
Accounting for improvements in survival when developing risk prediction models in a competing risks setting (abstract)
13:00-14:30 Session OC3D: Meta-analysis for prediction models
13:00
COVID-PRECISE: A living methodological review of prediction models for diagnosis and prognosis of covid-19 (abstract)
13:18
A Bayesian model for heterogeneous treatment effects on the additive risk scale in meta-analysis (abstract)
13:36
Assessing risk of bias in individual participant data meta-analyses for prediction model research (abstract)
13:54
Using meta-analysis for external validation of prediction models in big data, accounting for competing risks (abstract)
14:12
The Hierarchical Bias-Corrected Meta-Analysis Model (abstract)
13:00-14:30 Session OC3E: Multi-state model
13:00
MSMplus: A dynamic interactive web tool for presentation of multi-state model analysis results (abstract)
13:18
Statistical models for the natural history of breast cancer, with application to data from a Milan cohort study (abstract)
13:36
Reevaluating dementia incidence trends: The critical role of adequate design and methodology (abstract)
13:54
Statistical inference for transition probabilities in non-Markov multi-state models subject to both random left-truncation and right-censoring (abstract)
14:12
Harmonization of endpoints in ICU trials using multi-state modelling (abstract)
13:00-14:30 Session OC3F: Neural network and machine learning
13:00
Neural networks for survival prediction in medicine: a review and critical appraisal (abstract)
13:18
Comparison of imputation methods that solve granularity problem resulting from healthcare structured data integration. (abstract)
13:36
Survival Predictions and Uncertainty Measures with Censored Data (abstract)
13:54
Parametric and non-parametric variable selection methods for predictive modeling with binary response (abstract)
14:12
Performance measures for assessing machine learning algorithms in clinical trials (abstract)
13:00-14:30 Session OC3G: Study designs
13:00
Using Historical Data to Predict Health Outcomes – The Prediction Design (abstract)
13:18
Bayes Factors for Equivalence, Non-inferiority, and Superiority Designs Using baymedr (abstract)
13:36
FORECAST ALZHEIMER'S DISEASE PROGRESSION TO BETTER SELECT PATIENTS FOR CLINICAL TRIALS (abstract)
13:54
Design effects and analysis considerations for the split-mouth design with an unequal numbers of sites per patient (abstract)
14:12
Challenges of using big health data to identify patterns of anxiety and depression in multimorbid population (abstract)
14:30-15:00 Session P6: VIRTUAL POSTER ROOM : EPIDEMIOLOGY
14:30
The impact of left truncation of exposure in environmental case-control studies: evidence from breast cancer risk associated with airborne dioxin (abstract)
14:30
Lower Limit of Quantification in various distributed data: examining confidence interval variations (abstract)
14:30
Diversity indices and statistical methods used in studies addressing dysbiosis applied to composition data of the gut microbiota (abstract)
14:30
Subsequent primary neoplasms in bladder cancer patients (abstract)
14:30
On heuristic detection of maternal-age-related increase of birth defect risk: Experience, issues, alternatives (abstract)
14:30
Linkage of national clinical datasets without patient identifiers using probabilistic methods (abstract)
14:30
Chronic exposure to multiple air pollutant and risk of breast cancer: A nested case - control within the E3N cohort (abstract)
14:30
Use of innovative methods to estimate a reliable French pathological complete response rate on real world data (abstract)
14:30
Sensitivity analyses for measurement error using regression calibration or simulation-extrapolation (abstract)
15:15-16:45 Session IS4: INVITED : Challenges and opportunities for learning from long term disease registers
Discussant:
15:15
Data linkage for creating electronic birth cohorts: handling bias due to linkage error (abstract)
15:38
Challenges and opportunities for learning from long term disease registers: - Causal inference (abstract)
16:01
Methods for combining experimental and population data to estimate population average treatment effects (abstract)
15:15-16:45 Session IS5: INVITED : The best of both worlds: combining deep learning and modeling
15:15
Pharmacometrics-Informed Deep Learning with DeepNLME (abstract)
15:45
Temporal and relational machine learning for biostatistical and other scientific applications (abstract)
16:15
Individualizing deep dynamic models for psychological resilience data (abstract)
15:15-16:45 Session OC4A: Missing data in causal studies
15:15
Sensitivity to MNAR dropout in clinical trials: use and interpretation of the Trimmed Means Estimator (abstract)
15:33
Comparison of two causal inference methods for multiple treatments in clinical research on observational data (abstract)
15:51
Handling missing data for causal effect estimation in longitudinal cohort studies using Targeted Maximum Likelihood Estimation: a simulation study (abstract)
16:09
Estimands in clinical trials: making the hypothetical strategy concrete (abstract)
16:27
Incorporating baseline covariates to validate surrogate endpoints with a constant biomarker under control arm (abstract)
15:15-16:45 Session OC4B: Cluster randomized trials
15:15
Sample size calculation for stepped wedge cluster randomized trials with multiple levels of clustering (abstract)
15:33
Stepped-wedge cluster randomised trials with binary outcomes and small numbers of clusters: a case study (abstract)
15:51
Inference for the treatment effect in longitudinal cluster randomized trials when treatment effect heterogeneity is ignored (abstract)
16:09
Cluster randomised trials and a small number of clusters: Analysis method for a binary outcome (abstract)
16:27
Under what conditions do open-cohort cluster RCTs provide improvements over conventional designs? A simulation study. (abstract)
15:15-16:45 Session OC4C: Meta-analysis
15:15
Comparison of frequentist and Bayesian methods for two-arm borrowing of historical data (abstract)
15:33
Implications of Analysing Time-to-Event Outcomes as Binary in Meta-analysis (abstract)
15:51
Exploring non-linear treatment-covariate interactions at multiple time points using multivariate IPD meta-analysis (abstract)
16:09
A comprehensive framework for ‘deft’ (within-trials) interactions in meta-analysis (abstract)
16:27
Inclusion of real world data in surrogate endpoint evaluation: a Bayesian meta-analytic approach (abstract)
15:15-16:45 Session OC4D: Prediction model for omics data
15:15
Tailored Bayesian variable selection for risk prediction modelling under unequal misclassification costs (abstract)
15:33
Feature selection in multivariate varying-coefficient mixed models for drug response prediction (abstract)
15:51
Variational Bayes for Model Averaging for Multivariate models using Compositional Microbiome predictors (abstract)
PRESENTER: Darren Scott
16:09
Fast marginal likelihood estimation of penalties for group-adaptive elastic net (abstract)
16:27
Improving model performance estimation in high-dimensional data settings by using learning curves (abstract)
15:15-16:45 Session OC4E: competing risks and multi-state models
15:15
Bayesian inference for the direct approach for competing risk modeling with Gompertz distribution (abstract)
15:33
Analysis of competing risks data using restricted mean time lost (abstract)
15:51
Impact of competing event in COVID-19 clinical data analysis (abstract)
16:09
Parametric Landmark estimation of the transition probabilities in survival data with multiple events (abstract)
16:27
Phase I/II dose-finding design for right censored toxicity endpoints with competing disease progression (abstract)
16:45-17:15 Session P7: VIRTUAL POSTER ROOM : SURVIVAL ANALYSIS
16:45
Modeling Non-Proportional Hazards for Overall Survival Time for Cancer Treatments (abstract)
16:45
Sensitivity of results to missing data for clinical trials with discrete, longitudinal outcome measurements (abstract)
16:45
New Application of competing risks model in IgA nephropathy to explore the severity-dependent urinary remission (abstract)
16:45
Frailty Multi-state Model with Time-dependent Covariate for Prediction of Colorectal Cancer Progression (abstract)
16:45
Time to readmission among newborns: time for a reappraisal? (abstract)
16:45
Studying the longitudinal trajectory of potassium in heart failure patients through dynamic survival models (abstract)
16:45
Use of electronic health records to enhance data from a single clinical trial evaluating maintenance therapy in non-small cell lung cancer patients (abstract)
16:45
Modelling the length of stay of COVID-19 patients using a multistate approach (abstract)
16:45
Landmarking: An R package for analysis using landmark models (abstract)
16:45
The risk of valvular heart disease after childhood cancer: contribution of dose-volume histogram parameters (abstract)
16:45
The estimation of adjustment factors for expected mortality rates with application in comorbidity-adjusted lifetables (abstract)
16:45
Multiple Cox regression analysis to investigate a biomarker in IgA nephropathy disease: different approaches (abstract)
16:45
Analysis of Results of Total Knee Replacement Failure Using Cox Proportional Hazard Model with Time-Dependent Covariates (abstract)
16:45
Joint contribution of positive and total lymph nodes number in predicting overall survival of esophageal cancer (abstract)
16:45
Modelling the duration of recurrent events from interval-censored data (abstract)
16:45
Relation between women empowerment and birth interval: A survival analysis approach (abstract)
16:45
Impact of model choice when studying the relationship between blood pressure variability and risk of stroke (abstract)
16:45
A jack-knifed version of the log-rank test in small samples: when bias meets variance to increase test power (abstract)
17:30-19:00 Session IS6: INVITED : Causal inference in continuous time for dense longitudinal data from wearable devices
17:30
TMLE for Causal Effects based on continuous time longitudinal data structures (abstract)
18:00
The Impact of Time Series Length and Discretization on Longitudinal Causal Estimation Methods (abstract)
18:30
Missing data imputation for non-stationary time series in mHealth data (abstract)
17:30-19:00 Session OC5A: Bayesian clinical trial analysis
17:30
Bayesian joint modeling of a bivariate toxicity for dose-regimens in early phase oncology (abstract)
17:48
Interim analysis of a clinical trial using the predictive probability of success based on a surrogate endpoint (abstract)
18:06
Trials of Vaccine Efficacy for COVID-19: Inferential and Practical Issues (abstract)
18:24
Incorporating multiple parameters from historical controls using the meta-analytic-predictive (MAP) prior (abstract)
18:42
Bayesian hierarchical modeling for MedDRA coded adverse events in RCTs (abstract)
17:30-19:00 Session OC5B: Prediction by Machine learning
17:30
Individual risk prediction: comparing Random Forests with Cox proportional-hazards model by a simulation study (abstract)
17:48
Predicting patient mortality from large sets of diagnosis codes using logistic regression and machine learning (abstract)
18:06
Predicting individual life years lost due to cancer using pseudo-observations with random forest, in the absence of cause of death information (abstract)
18:24
A comprehensive comparison of approaches for the calibration of probability machines (abstract)
18:42
Methodological conduct of clinical prediction models using machine learning methods in oncology needs to be improved (abstract)
17:30-19:00 Session OC5C: Screening and Diagnostic studies
17:30
The Natural History of Invasive Breast Cancers Detected in the Scandinavian Mammography Screening Programs: A Cohort Study (abstract)
17:48
Meta-analysis of dichotomous and polytomous diagnostic tests without a gold standard (abstract)
18:06
Comparison of methods for the linear combination of biomarkers under Youden Index optimisation criterion (abstract)
18:24
Single and multiple imputation combined with missing indicators in clinical prediction models: a simulation study (abstract)
18:42
Diagnosing Latent Class Analysis for Analyzing Diagnostic Tests in the Absence of a Gold Standard (abstract)
17:30-19:00 Session OC5D: Bayesian Joint models for longitudinal data and time-to-event
17:30
Bayesian multilevel nonlinear joint model to characterize the variability in the response to immunotherapy (abstract)
17:48
Multistate inference based on longitudinal/competing risks joint modeling under misclassified cause of failure (abstract)
18:06
Bayesian Predictive Model Averaging for Joint Model of Survival and Longitudinal Data: Application to an Immunotherapy Trial (abstract)
18:24
A Joint Model for Multiple Longitudinal Outcomes, Recurrent and Terminal Events using CF Patient Registry Data (abstract)
18:42
Joint Modeling of Incomplete Longitudinal Data and Time-to-Event Data (abstract)
17:30-19:00 Session OC5E: cure and mixture models
17:30
RECeUS: Ratio Estimation of Censored Uncured Subjects for Studying Sufficient Follow-Up in Studies of Long-Term Survivors (abstract)
17:48
Multiple imputation for survival analysis with missing data and a cure fraction: a study of osteosarcoma (abstract)
18:06
A simulation analysis of reliability and robustness of a cancer cure model accounting for extra non-cancer mortality. (abstract)
18:24
An extension of Fellegi-Sunter record linkage model for mixed-type data with application to SNDS (abstract)
17:30-19:00 Session OC5F: longitudinal data analysis :
17:30
Multiple imputation approaches for handling incomplete three-level data with time varying cluster memberships (abstract)
17:48
Separation in Marginal Logistic Regression Models (abstract)
18:06
A geometric Brownian motion model with non-normal random effect for the prediction of the growth of abdominal aortic aneurysms (abstract)
18:24
Predicting Patient Risk for Adverse Drug Events in Health Care Claims Data using Functional Targets (abstract)
18:42
Bayesian Path Analysis Models with Variable Selection for high-dimensional and longitudinal Genetic Epidemiology (abstract)
17:30-19:00 Session OC5G: Missing data & measurement error
17:30
Multiple imputation for missing data in case-cohort studies: simulation and case study (abstract)
17:48
Application of three level multiple imputation to national surveys (abstract)
18:06
Profiles of COVID 19-Hematological patients: Franco-Brazilian observational cohort study (abstract)
18:24
Prediction of cancer incidence in areas without registries using proxy and registry data (abstract)
18:42
What is the real prevalence of hypertension in France ? (abstract)
19:00-19:30 Session P8: VIRTUAL POSTER ROOM : EPIDEMIC MODELING
19:00
Exploring the Sensitivity of Extended SIR Models Through Randomized Simulations and Multiple Factor Analysis (abstract)
19:00
Monte Carlo simulation of the COVID-19 spread using an agent-based modelling in Russian regions (abstract)
19:00
Similarities between the COVID-19 spread in Romanian counties identified through data clustering (abstract)
19:00
A new epidemic model for the Covid-19 pandemic (abstract)
19:00
Spatial analyses of the first wave of COVID-19 cases in Hong-Kong using Poisson intrinsic and Besag York Mollié conditional autoregressive models under a Bayesian paradigm (abstract)
19:00
Indices of inequality to monitor temporal and geographic trends in COVID-19 incidence and death data (abstract)
19:00
Bayesian disease mapping of standardized infection fatality rate using the example of COVID-19 in Bavaria (abstract)
19:00
Mathematical Modelling of COVID-19 Epidemics in Tokyo Metropolitan and New York City (abstract)
19:00
Application of a spatio-temporal SVEIRD model to COVID-19 epidemic in the Czech Republic (abstract)
19:00
Impact of STI screening intensity on antibiotic exposure: A modelling study among men who have sex with men in Belgium (abstract)
19:00
Epilocal: A real-time tool for local epidemic monitoring (abstract)
Wednesday, July 21st

View this program: with abstractssession overviewtalk overview

13:00-14:30 Session IS7: INVITED : Selective inference after variable selection
13:00
Valid post-selection inference for cox regression parameters, with and without the proportional hazards assumption. (abstract)
13:30
Selective inference for the Lasso in statistical practice (abstract)
14:00
Biologically-informed development of treatment selection scores from high-dimensional omics data (abstract)
13:00-14:30 Session OC6A: causal inference
13:00
Incident and prevalent-user designs and the definition of study time origin in pharmacoepidemiology: a systematic review (abstract)
13:18
A framework for meta-analysis of studies with baseline exposure through standardized survival curves (abstract)
13:36
Causal inference in practice: two case studies in nephrology (abstract)
13:54
Machine learning, G-computation and small sample sizes: a simulation study (abstract)
14:12
Valid Uncertainty Interval for the Average Causal Effect in a High-dimensional Settingv (abstract)
13:00-14:30 Session OC6B: Adaptive clinical trial design
13:00
Adaptive designs for three-arm gold-standard non-inferiority trials (abstract)
13:18
A comparison of estimation methods adjusting for selection bias in adaptive enrichment designs with time-to-event endpoints (abstract)
13:36
A stochastically curtailed two-arm randomised phase II trial design for binary outcomes (abstract)
13:54
Fast-tracking clinical trial innovations – a COVID-19 silver lining (abstract)
14:12
Adaptive clinical trials with selection of composite endpoints and sample size reassessment (abstract)
13:00-14:30 Session OC6C: Joint models &2-stage approach
13:00
Marginalized two-part joint modeling of longitudinal semi-continuous responses and survival data: with application to medical expenses (abstract)
13:18
Healthy life expectancy computation using the Item Response Theory combined with a joint modeling approach (abstract)
13:36
Modelling the effect of longitudinal latent toxicity profiles on survival: an application to osteosarcoma (abstract)
13:54
Joint model versus linear mixed model to analyze longitudinal data of health-related quality of life in cancer clinical trials (abstract)
14:12
Joint modelling of the temporal relationships between multivariate longitudinal markers of Alzheimer’s disease progression and clinical endpoints (abstract)
13:00-14:30 Session OC6D: Time-to-event methods for non-proportional hazards
13:00
Methods for analyzing time-to-event endpoints in immuno-oncological trials with delayed treatment effects (abstract)
13:18
Non-proportional hazards in immuno-oncology: Is an old perspective needed? (abstract)
13:36
Weighted hazard ratio for time to event endpoints under non proportional hazards (abstract)
13:54
Comparison of statistical methods for estimating time-varying treatment effect on adverse event risk (abstract)
14:12
Evidence Synthesis of Time-To-Event Outcomes in the Presence of Non-Proportional Hazards (abstract)
13:00-14:30 Session OC6E: relative survival and net benefit estimation
13:00
Additional benefit method assessment for time-to-event endpoints – A comparison of ESMOs and IQWiGs approach (abstract)
13:18
Obtaining long-term stage-specific relative survival estimates in the presence of incomplete historical stage information (abstract)
13:36
A latent class model for the estimation of the excess mortality hazard for correcting inaccurate background mortality (abstract)
13:54
Robust statistical inference for the matched net benefit and win ratio. (abstract)
14:12
A unifying framework for flexible excess hazard modeling with applications in cancer epidemiology (abstract)
13:00-14:30 Session OC6F: Deep learning
13:00
Cluster analysis on emergency COVID-19 data: A result-based multiple imputation for missing data (abstract)
13:18
Statistical Power for Single Cell Representations (abstract)
13:36
Effects of Interactions and Dataset Size in Neural Networks and Other Machine Learning Approaches (abstract)
13:54
CamemBERT word-embedding for Information Extraction in a Biomedical Context (abstract)
14:12
Interpretable effect estimates of semi-structured predictors in deep distributional regression models (abstract)
14:30-15:00 Session P9: VIRTUAL POSTER ROOM : INDIVIDUAL PREDICTION AND PRECISION MEDICINE
14:30
A Bayesian nonparametric approach for modeling SF-6D health state utility scores (abstract)
14:30
Small-sample accuracy of approximations of individual polynomial growth curves’ prediction error in linear mixed regression (abstract)
14:30
Assessment of performance measures for external validation of multivariable prediction models: Simulations (abstract)
14:30
Mathematical proof of the equivalence between Post-test Predictive Probabilities and Predictive Values (abstract)
14:30
Development and validation of a clinical risk score to predict the risk of SARS-CoV-2 infection from administrative data (abstract)
14:30
Subject-specific networks as features for predictive modelling - A scoping review of methods (abstract)
14:30
Individual dynamic predictions in joint analysis of non-linear longitudinal model and parametric competing risk model: application to sepsis patients (abstract)
14:30
Estimating the treatment selection ability of a marker: review, comparison, and improvement of existing approaches (abstract)
14:30
Double cut-point identification of continuous diagnostic test variables for clinical use (abstract)
14:30
Patient heterogeneity assessments via network-based ANOVA (abstract)
14:30
A comparison of prioritisation tools for CVD risk assessment in UK Biobank: Primary care records versus polygenic risk scores (abstract)
14:30
Operational characteristics of generalized pairwise comparisons for hierarchically ordered endpoints (abstract)
14:30
Landmark Prediction of Survival for HIV-infected Patients by Considering AIDS as an Intermediate Event (abstract)
15:15-16:45 Session IS8: INVITED : Variance modelling for multilevel data and joint models
15:15
A general framework and implementation for variance modelling in joint model settings (abstract)
15:45
Dynamic structural equation modeling for intensive longitudinal data (abstract)
16:15
Jointly modelling longitudinal heteroscedasticity and a time-to-event outcome (abstract)
15:15-16:45 Session OC7A: Causal inference in survival analysis
15:15
Marginal structural Cox models in nested case-control studies with time-varying treatments (abstract)
15:33
Benefit-based organ allocation in liver transplantation (abstract)
15:51
Extending multistate models with g-computation to evaluate the effect of treatment timing (abstract)
16:09
Causal assessment of surrogacy for time-to-event endpoints using meta-analytic data (abstract)
16:27
Estimating treatment effects on survival in an entirely treated cohort: negative controls in longitudinal data (abstract)
15:15-16:45 Session OC7B: Clinical trial design and sample size calculation
15:15
Analysis and sample size calculation for a survival model conditional on a binary surrogate endpoint (abstract)
15:33
Dangers of wrongly assuming linearity in a trial sample size calculation when treatment affects rate of change (abstract)
15:51
Estimating sample size for biomarker-strategy designs with survival endpoints (abstract)
16:09
Multidimensional Go/No-Go decision rules (abstract)
16:27
Online control of the False Discovery Rate in platform trials (abstract)
15:15-16:45 Session OC7C: frailty model and recurrent events
15:15
A non-mixture cure model with frailty correction for inaccurate background mortality to estimate time-to-cure. (abstract)
15:33
A family of discrete random effect distributions for modelling bivariate time-to-event data (abstract)
15:51
A general approach to fit flexible hazard regression models with multiple random effects (abstract)
16:09
Handling recurrent events in the context of clinical trials (abstract)
16:27
Retro-prospective modelling of recurrent events (abstract)
15:15-16:45 Session OC7D: functional data analysis
15:15
Trajectory clustering using mixed classification models (abstract)
15:33
Bayesian concurrent functional regression for sensor data (abstract)
15:51
ERNEST: A Representation Learning-based Cross-Subject EEG Channel Selection Algorithm (abstract)
16:09
Linear statistical models and ridge regression used in shape index calculation on human face (abstract)
16:27
Unsupervised classification of ECG signals via FDA to look for different patterns of variation among patients (abstract)
15:15-16:45 Session OC7E: Selection and validation of prediction models
15:15
To tune or not to tune, a case study of ridge logistic regression in small or sparse datasets (abstract)
15:33
Propensity-based standardization to enhance the interpretation of prediction model discrimination (abstract)
15:51
A novel score for prognostic index assessment with event-free survival outcome (abstract)
16:09
Minimum sample size for external validation of a clinical prediction model with a binary or time-to-event outcome (abstract)
16:27
The nonnegative garrote as a flexible approach for model selection in low and high dimensional data (abstract)
15:15-16:45 Session OC7F: flexible modelling and spatial data analysis
15:15
Conditional and unconditional logistic regression analysis of matched case-control studies of recurrent events (abstract)
15:33
On the implications of influential points for the selection and reproducibility of MFP models (abstract)
15:51
Worldwide age specific Human Papillomavirus prevalence patterns: a mixed effects binomial method to cluster trajectories (abstract)
16:09
Treating ordinal outcomes as continuous quantities: when, why and how. (abstract)
16:27
Health map for HealthGap: Defining a geographical catchment to examine cardiovascular risk in Australia (abstract)
15:15-16:45 Session OC7G: Methods for clinical research
15:15
Bayesian extrapolation from pre-clinical data to human (abstract)
15:33
Analysing ordinal endpoints in two-arm randomized clinical trials (abstract)
15:51
Simulations to assess the impact of non-adherance due to COVID-19 in a cluster-randomized non-inferiority trial (abstract)
16:09
Analysis methods for personalized randomized controlled trial (PRACTical) (abstract)
16:27
MultiNet: a computational algorithm to analyze high-dimensional epigenetic correlation structures (abstract)
17:00-18:00 Session Plenary 2: KEYNOTE INVITED SPEAKER
17:00
HANDLING NEGATIVE CORRELATION AND/OR OVER/UNDERDISPERSON IN GAUSSIAN AND NON-GAUSSIAN HIERARCHICAL DATA (abstract)
19:00-19:30 Session P10: VIRTUAL POSTER ROOM : META ANALYSIS
19:00
Video-Assisted Non-Intubated Lobectomies for Lung Cancer: A Systematic Review and Meta-Analysis (abstract)
19:00
Bias in evaluation of discrete surrogate outcomes, due to separation: a penalized likelihood solution (abstract)
19:00
Developing a Novel Interactive Multifaceted Graphic for Treatment Ranking within Network Meta-Analysis (abstract)
19:00
Propensity Score-Integrated Meta-Analytic-Predictive Priors (abstract)
19:00
Using threshold analysis to assess the robustness of public health intervention recommendations from network meta-analyses (abstract)
19:00
Meta-analysis methods used in systematic reviews of interrupted time series studies (abstract)
19:00
Effects of probiotics on mortality and morbidity in preterm infants: a Bayesian network meta-analysis of randomized and non-randomized studies (abstract)
19:00
Kenward-Roger-type corrections for network meta-analysis and meta-regression (abstract)